Cargando…

HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2

Increasing evidence suggests that dysregulation of long non-coding RNAs (lncRNAs) is implicated in chemoresistance in cancers. However, the function and molecular mechanisms of lncRNAs in gastric cancer chemoresistance are still not well understood. In this study, we aimed to investigate the functio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Yafei, Yang, Shengnan, Han, Yanping, Sun, Jingjing, Xv, Lijuan, Wu, Lina, Ming, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769292/ https://www.ncbi.nlm.nih.gov/pubmed/31551012 http://dx.doi.org/10.1098/rsob.190068

Ejemplares similares

Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al.
Publicado: (2023)

Linc00472 suppresses proliferation and promotes apoptosis through elevating PDCD4 expression by sponging miR-196a in colorectal cancer
por: Ye, Yafei, et al.
Publicado: (2018)

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
por: Xu, Caihui, et al.
Publicado: (2018)

LINC-PINT suppresses cisplatin resistance in gastric cancer by inhibiting autophagy activation via epigenetic silencing of ATG5 by EZH2
por: Zhang, Cheng, et al.
Publicado: (2022)

EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
por: Dou, Dongwei, et al.
Publicado: (2019)

A Genetic Approach to the Recruitment of PRC2 at the HoxD Locus
por: Schorderet, Patrick, et al.
Publicado: (2013)

Epigenetic repression of the Igk locus by STAT5-mediated Ezh2 recruitment
por: Mandal, Malay, et al.
Publicado: (2011)

Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma
por: Guo, Yulin, et al.
Publicado: (2017)

A pan-cancer analysis of the role of HOXD1, HOXD3, and HOXD4 and validation in renal cell carcinoma
por: Wang, Lumin, et al.
Publicado: (2023)

EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion
por: Yi, Xiaoqing, et al.
Publicado: (2017)

Epigenetic Silencing of miR-9 Promotes Migration and Invasion by EZH2 in Glioblastoma Cells
por: Chien, Yi-Chung, et al.
Publicado: (2020)

Attenuated Acceleration to Leukemia after Ezh2 Loss in Nup98-HoxD13 (NHD13) Myelodysplastic Syndrome
por: Ling, Victoria Y., et al.
Publicado: (2019)

LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway
por: Dai, Qingqiang, et al.
Publicado: (2020)

Hoxd10 Is Required Systemically for Secretory Activation in Lactation and Interacts Genetically with Hoxd9
por: Landua, John D., et al.
Publicado: (2020)

Hypermethylation and Expression Silencing of PDCD4 Gene in Hepatocellular Carcinoma: A Consort Study
por: Ding, Xianglian, et al.
Publicado: (2016)

P38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim
por: Hu, Ping, et al.
Publicado: (2018)

EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c
por: Xu, Leibo, et al.
Publicado: (2020)

Making HoxD waves
por: Katsnelson, Alla
Publicado: (2006)

PDCD5 transfection increases cisplatin sensitivity and decreases invasion in hepatic cancer cells
por: FAN, GUI-LING, et al.
Publicado: (2015)

Evx2-Hoxd13 Intergenic Region Restricts Enhancer Association to Hoxd13 Promoter
por: Yamagishi, Takumi, et al.
Publicado: (2007)

Ovarian cancer variant rs2072590 is associated with HOXD1 and HOXD3 gene expression
por: Guo, Liyuan, et al.
Publicado: (2017)

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2
por: Li, Bo, et al.
Publicado: (2019)

A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis
por: Coward, William R., et al.
Publicado: (2014)

TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer
por: Gui, Tao, et al.
Publicado: (2021)

LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTEN via EZH2
por: Zhao, Dan, et al.
Publicado: (2019)

Upregulation of lncRNA LINC00460 Facilitates GC Progression through Epigenetically Silencing CCNG2 by EZH2/LSD1 and Indicates Poor Outcomes
por: Yang, Jiebin, et al.
Publicado: (2020)

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer
por: Sun, PengMing, et al.
Publicado: (2018)

Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer
por: Shindo, Tetsuya, et al.
Publicado: (2018)

Point Mutation of Hoxd12 in Mice
por: Cho, Kyoung-Won, et al.
Publicado: (2008)

HOXD9 Activates the TGF-β/Smad Signaling Pathway to Promote Gastric Cancer
por: Xiong, Rui, et al.
Publicado: (2020)

Decreased expression of the long non-coding RNA HOXD-AS2 promotes gastric cancer progression by targeting HOXD8 and activating PI3K/Akt signaling pathway
por: Yao, Lin, et al.
Publicado: (2020)

EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer
por: Chinaranagari, Swathi, et al.
Publicado: (2014)

PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis
por: Gao, Fei, et al.
Publicado: (2009)

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
por: Palomeras, Sònia, et al.
Publicado: (2019)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2019)

Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2022)

High HOXD4 protein expression in gastric adenocarcinoma tissues indicates unfavorable clinical outcomes
por: Liu, Hui, et al.
Publicado: (2019)

EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression
por: Wang, Chenyu, et al.
Publicado: (2018)

ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer
por: Kunderfranco, Paolo, et al.
Publicado: (2010)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1s26lkapp6uvo0v3o63ua7qn3i